GLP-1 Receptor Agonist (Oral)
Pregnancy: Contraindicated — use insulin in pregnancy. Stop at least 2 months before planned conception.
Semaglutide (Oral)
Brand names: Rybelsus
Adult dose
Dose: Starting: 3mg OD for 30 days; increase to 7mg OD for 30 days; increase to 14mg OD if further HbA1c reduction needed
Route: Oral tablet
Frequency: Once daily — must be taken on an empty stomach, with up to 120mL water, at least 30 minutes before any food/drink/other medication
Max: 14mg OD
Oral GLP-1 RA — requires specific administration conditions (empty stomach, small volume water, 30 min fast after) to ensure adequate absorption. If a dose is missed and >12h until next dose, skip; if <12h, take as soon as remembered. Different pharmacokinetics to injectable semaglutide (Ozempic/Wegovy).
Paediatric dose
Route: Oral
Frequency: Once daily
Max: Not applicable
Not licensed under 18 years. Seek specialist opinion.
Dose adjustments
Renal
No dose adjustment required for any degree of renal impairment (PIONEER studies included eGFR ≥15).
Hepatic
No dose adjustment in mild-moderate hepatic impairment. Severe: limited data.
Clinical pearls
- PIONEER trials: oral semaglutide 14mg non-inferior to injectable dulaglutide 0.75mg and superior to empagliflozin for HbA1c reduction
- Administration technique critical for efficacy — inadequate absorption if taken with food, large volumes of water, or other medications. Counsel carefully.
- Weight loss ~3–4kg at 14mg dose — less than injectable semaglutide (Ozempic/Wegovy) due to lower bioavailability
- Rybelsus (oral) and Ozempic (injectable weekly) are both semaglutide — do NOT prescribe together
Contraindications
- Personal/family history of medullary thyroid carcinoma
- MEN type 2
- Type 1 DM
- eGFR <15 (limited data)
- Hypersensitivity to semaglutide
Side effects
- Nausea (very common, dose-related, usually transient)
- Vomiting
- Diarrhoea
- Constipation
- Decreased appetite
- Pancreatitis (rare)
- Gallbladder disease
Interactions
- Oral medications — delayed gastric emptying may reduce absorption; take time-critical drugs (levothyroxine, hormonal contraceptives) well before Rybelsus or follow specific separation guidance
- Warfarin — monitor INR
- Sulphonylureas — additive hypoglycaemia
Monitoring
- HbA1c 3–6 monthly
- Weight and BMI
- GI side effects (guide dose titration)
- Lipase if abdominal symptoms
Reference: BNFc; BNF 90; NICE NG28 (Type 2 DM); PIONEER Trials (NEJM 2019). Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
Pathways
- Diabetic Ketoacidosis (DKA) · JBDS 2013 / Joint British Diabetes Societies; NICE NG17
- Adult Hypoglycaemia (Treated Diabetes) · JBDS-IP (2023): Hospital Management of Hypoglycaemia
- Adrenal Crisis · Society for Endocrinology Emergency Guidance (2024)
- Type 2 Diabetes Management · NICE NG28 2022
- Hyperthyroidism Management · BTA / ETA 2018
- Adrenal Insufficiency · Society of Endocrinology / ESE 2016